129. Nat Commun. 2018 May 22;9(1):2071. doi: 10.1038/s41467-018-04198-5.Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhancestumor cell killing by p53 degradation blockage.Ladds MJGW(1)(2), van Leeuwen IMM(1), Drummond CJ(1), Chu S(3), Healy AR(4),Popova G(1), Pastor Fernández A(1), Mollick T(1)(2), Darekar S(1)(2), SedimbiSK(1)(2), Nekulova M(1)(5), Sachweh MCC(1), Campbell J(6), Higgins M(6), TuckC(1), Popa M(7), Safont MM(7), Gelebart P(7), Fandalyuk Z(7), Thompson AM(8),Svensson R(9), Gustavsson AL(10), Johansson L(10), Färnegårdh K(11), Yngve U(12),Saleh A(12), Haraldsson M(11), D'Hollander ACA(4), Franco M(1), Zhao Y(13),Håkansson M(14), Walse B(14), Larsson K(1), Peat EM(15), Pelechano V(2), LunecJ(13), Vojtesek B(5), Carmena M(15), Earnshaw WC(15), McCarthy AR(1), WestwoodNJ(4), Arsenian-Henriksson M(1), Lane DP(1)(2), Bhatia R(3), McCormack E(7)(16), Laín S(17)(18).Author information: (1)Department of Microbiology, Tumor and Cell Biology (MTC), KarolinskaInstitutet, SE-171 77, Stockholm, Sweden.(2)SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC),Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden.(3)Division of Hematology and Oncology, Comprehensive Cancer Center, 1720 2ndAvenue South, NP2540, Birmingham, AL, 35294-3300, USA.(4)School of Chemistry and Biomedical Sciences Research Complex, University ofSt. Andrews and EaStCHEM, St. Andrews, Fife, Scotland, KY16 9ST, UK.(5)RECAMO, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 65653, Brno, CzechRepublic.(6)Centre for Oncology and Molecular Medicine, University of Dundee, NinewellsHospital and Medical School, Dundee, Tayside, DD1 9SY, UK.(7)Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science,Hematology Section, University of Bergen, 5021, Bergen, Norway.(8)Department of Breast Surgical Oncology, MD Anderson Cancer Center, HolcombeBoulevard, Houston, 77030, USA.(9)Department of Pharmacy, Uppsala University Drug Optimization andPharmaceutical Profiling Platform (UDOPP), Department of Pharmacy, UppsalaUniversity, SE-752 37, Uppsala, Sweden.(10)Chemical Biology Consortium Sweden, Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistryand Biophysics, Karolinska Institutet, SE-171 21, Stockholm, Sweden.(11)Drug Discovery and Development Platform, Science for Life Laboratory,Tomtebodavägen 23, SE-171 21, Solna, Sweden.(12)Department of Medicinal Chemistry, Science for Life Laboratories, UppsalaUniversity, SE-751 23, Uppsala, Sweden.(13)Newcastle Cancer Centre, Northern Institute for Cancer Research, NewcastleUniversity, Newcastle, NE1 7RU, UK.(14)SARomics Biostructures, Medicon Village, SE-223 81, Lund, Sweden.(15)The Wellcome Trust Centre for Cell Biology, Institute of Cell Biology,University of Edinburgh, Edinburgh, EH9 3JR, UK.(16)Department of Medicine, Haematology Section, Haukeland University Hospital,Bergen, Norway.(17)Department of Microbiology, Tumor and Cell Biology (MTC), KarolinskaInstitutet, SE-171 77, Stockholm, Sweden. sonia.lain@ki.se.(18)SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC),Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden.sonia.lain@ki.se.Erratum for    Nat Commun. 2018 Mar 16;9(1):1107.The original PDF version of this Article listed the authors as "Marcus J.G.W.Ladds," where it should have read "Marcus J. G. W. Ladds, Ingeborg M. M. vanLeeuwen, Catherine J. Drummond et al.#".Also in the PDF version, it wasincorrectly stated that "Correspondence and requests for materials should beaddressed to S. Lín.", instead of the correct "Correspondence and requests formaterials should be addressed to S. Laín."This has been corrected in the PDFversion of the Article. The HTML version was correct from the time ofpublication.DOI: 10.1038/s41467-018-04198-5 PMCID: PMC5964109PMID: 29789663 